Day One Biopharmaceuticals (DAWN) Expected to Announce Quarterly Earnings on Tuesday

Day One Biopharmaceuticals (NASDAQ:DAWN) is projected to announce its earnings results after the market closes on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Day One Biopharmaceuticals Stock Performance

NASDAQ DAWN opened at $12.43 on Friday. Day One Biopharmaceuticals has a twelve month low of $11.13 and a twelve month high of $18.07. The stock has a market capitalization of $1.25 billion, a PE ratio of -12.07 and a beta of -1.46. The stock has a 50-day simple moving average of $12.37 and a 200 day simple moving average of $13.47.

Analysts Set New Price Targets

Several equities analysts recently weighed in on DAWN shares. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. The Goldman Sachs Group cut their price objective on Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a research report on Monday, February 10th. TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. Bank of America cut their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Monday, January 13th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $35.71.

Insider Buying and Selling at Day One Biopharmaceuticals

In related news, General Counsel Adam Dubow sold 4,646 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $55,566.16. Following the sale, the general counsel now directly owns 39,602 shares in the company, valued at $473,639.92. This represents a 10.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Charles N. York II sold 4,370 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $52,265.20. Following the sale, the chief financial officer now owns 252,638 shares in the company, valued at approximately $3,021,550.48. This trade represents a 1.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 51,064 shares of company stock valued at $651,225 in the last quarter. Corporate insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.